FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1731-1733 December 2, 1993 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Administration of a glucocorticoid by inhalation has assumed a prominent role in the treatment of asthma in both children and adults. The reasons are that asthma is now viewed as a disease with an important inflammatory component and that there are inhaled glucocorticoid preparations that are highly active topically yet weakly active systemically, which minimizes the risks of suppressing endogenous pituitary-adrenal function and causing iatrogenic Cushing's syndrome.

The glucocorticoids used most widely for inhalation therapy -- beclomethasone dipropionate and budesonide (the latter not available in the United States) -- have very high affinity for intracellular glucocorticoid receptors but are rapidly . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bisgaard, H., Allen, D., Milanowski, J., Kalev, I., Willits, L., Davies, P. (2004). Twelve-Month Safety and Efficacy of Inhaled Fluticasone Propionate in Children Aged 1 to 3 Years With Recurrent Wheezing. Pediatrics 113: e87-94 [Abstract] [Full Text]